Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075893 | 0.86 | ESR1 (0.37) | ESR1ESR2TOP1 | |
| SCHEMBL26075942 | 0.86 | DHFR (0.39) | ESR1ESR2ALOX5APFEN1 | |
| SCHEMBL26075885 | 0.81 | HMOX1 (0.41) | ESR1ESR2 | |
| SCHEMBL26075865 | 0.80 | ACACA (0.46) | — | |
| SCHEMBL26075894 | 0.80 | ESR1 (0.37) | ESR1ESR2TOP1 | |
| SCHEMBL26075867 | 0.80 | PLA2G2A (0.42) | DHODH | |
| SCHEMBL26075866 | 0.80 | DHODH (0.43) | DHODH | |
| SCHEMBL26075889 | 0.79 | ESR1 (0.38) | ESR1ESR2TOP1DHODH | |
| SCHEMBL26075902 | 0.78 | NCF1 (0.37) | ESR1ESR2DHODH | |
| SCHEMBL26075891 | 0.78 | DHODH (0.44) | ESR1ESR2TOP1DHODHFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | ESR1 4427/4885ESR2 4530/4885LATS1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.